Fragile X treatment KER-0193 gets FDA orphan, rare disease tags
The FDA has granted orphan drug and rare pediatric disease designations to fragile X treatment KER-0193, Kaerus Biosciences said.| Fragile X News Today
The FDA has granted orphan drug and rare pediatric disease designations to fragile X treatment KER-0193, Kaerus Biosciences said.| Fragile X News Today
The FDA has approved a Phase 2 trial to test SPG601, an oral treatment candidate, in men with fragile X syndrome.| Fragile X News Today
Fragile X-causing mutations in FMR1 cause structural DNA changes that affect other genes necessary for nerve cell function, a study says.| Fragile X News Today
